Education
About Us
Working with TipRanks
Follow Us
Paradigm Biopharmaceuticals Ltd. (AU:PAR)
ASX:PAR
Total Valuation
Paradigm Biopharmaceuticals Ltd. has a market cap or net worth of $116.83M. The enterprise value is AU$71.72M.
Market Cap$116.83M
Enterprise ValueAU$71.72M
Share Statistics
Paradigm Biopharmaceuticals Ltd. has 389,428,830 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding389,428,830
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Paradigm Biopharmaceuticals Ltd.’s return on equity (ROE) is -2.46 and return on invested capital (ROIC) is -244.70%.
Return on Equity (ROE)-2.46
Return on Assets (ROA)-2.14
Return on Invested Capital (ROIC)-244.70%
Return on Capital Employed (ROCE)-2.71
Revenue Per Employee―
Profits Per Employee―
Employee Count―
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Paradigm Biopharmaceuticals Ltd. is -1.45. Paradigm Biopharmaceuticals Ltd.’s PEG ratio is -0.13.
PE Ratio-1.45
PS Ratio6584.01
PB Ratio3.57
Price to Fair Value3.57
Price to FCF-1.29
Price to Operating Cash Flow-1.29
PEG Ratio-0.13
Income Statement
In the last 12 months, Paradigm Biopharmaceuticals Ltd. had revenue of 65.80K and earned -58.65M in profits. Earnings per share was -0.20.
Revenue65.80K
Gross Profit56.81K
Operating Income-65.19M
Pretax Income-64.70M
Net Income-58.65M
EBITDA-64.54M
Earnings Per Share (EPS)-0.20
Cash Flow
In the last 12 months, operating cash flow was -23.14M and capital expenditures 14.92M, giving a free cash flow of -8.22M billion.
Operating Cash Flow-23.14M
Free Cash Flow-8.22M
Free Cash Flow per Share-0.02
Dividends & Yields
Paradigm Biopharmaceuticals Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.71
52-Week Price Change11.11%
50-Day Moving Average0.42
200-Day Moving Average0.34
Relative Strength Index (RSI)40.05
Average Volume (3m)878.17K
Important Dates
Paradigm Biopharmaceuticals Ltd. upcoming earnings date is Aug 29, 2025, TBA Not Confirmed.
Last Earnings DateFeb 27, 2025
Next Earnings DateAug 29, 2025
Ex-Dividend Date―
Financial Position
Paradigm Biopharmaceuticals Ltd. as a current ratio of 7.22, with Debt / Equity ratio of 0.53%
Current Ratio7.22
Quick Ratio7.22
Debt to Market Cap0.00
Net Debt to EBITDA0.27
Interest Coverage Ratio-4.54K
Taxes
In the past 12 months, Paradigm Biopharmaceuticals Ltd. has paid -6.05M in taxes.
Income Tax-6.05M
Effective Tax Rate0.09
Enterprise Valuation
Paradigm Biopharmaceuticals Ltd. EV to EBITDA ratio is -1.05, with an EV/FCF ratio of -1.02.
EV to Sales1.03K
EV to EBITDA-1.05
EV to Free Cash Flow-1.02
EV to Operating Cash Flow-1.02
Balance Sheet
Paradigm Biopharmaceuticals Ltd. has $24.78M in cash and marketable securities with AU$36.63K in debt, giving a net cash position of -$24.60M billion.
Cash & Marketable Securities$24.78M
Total DebtAU$36.63K
Net Cash-$24.60M
Net Cash Per Share-$0.06
Tangible Book Value Per Share$0.07
Margins
Gross margin is 66.42%, with operating margin of -99077.69%, and net profit margin of -89138.58%.
Gross Margin66.42%
Operating Margin-99077.69%
Pretax Margin-98328.73%
Net Profit Margin-89138.58%
EBITDA Margin-98083.89%
EBIT Margin-98306.89%
Analyst Forecast
The average price target for Paradigm Biopharmaceuticals Ltd. is $0.80, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$0.80
Price Target Upside165.74% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast96.20%
EPS Growth Forecast80.90%